Results 81 to 90 of about 1,498,446 (168)

DE NOVO PARKİNSON HASTALARINDA ANTİPARKİNSON İLAÇLARIN OKULER ETKİLERİ

DE NOVO PARKİNSON HASTALARINDA ANTİPARKİNSON İLAÇLARIN OKULER ETKİLERİ ÖZET Amaç: Parkinson hastalığı (PH), yaşlı nüfusta sık görülen ilerleyici bir nörodejeneratif hastalıktır.
MERVE ERGÜN
core  

Hypotensive Episodes Precede Cognitive Fluctuations in Parkinson's Disease Dementia. [PDF]

Mov Disord Clin Pract
Patino J, Duque K, Abanto J, Bloemer A, Deraz H, Espay AJ, Mahajan A.   +6 more
europepmc   +1 more source

Drug interaction (19. combination with antiparkinson agents)

Okayama Igakkai Zasshi (Journal of Okayama Medical Association), 2010
Ezumi, Satoru, Kuroda, Satoshi, Matsunaga, Hisashi, Sendo, Toshiaki   +3 more
openaire   +2 more sources

Parkinsonism in Idiopathic Normal Pressure Hydrocephalus or Hydrocephalic Presentation in Parkinson's Disease: A Report of Three Cases. [PDF]

Intern Med
Yoshihama R, Ohara M, Matsubayashi T, Hattori T.   +3 more
europepmc   +1 more source

Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists in Parkinson Disease: A Systematic Review and Meta-Analysis. [PDF]

Brain Behav
Raza H, Nizam B, Padaniya A, Farid MA, Nabi A, Hasan MQ, Salih M, Patel AH, Inam N, Rehman MEU, Khan U, Alsubari AMA.   +11 more
europepmc   +1 more source

Racial and Ethnic Diversity in Clinical Trials for Disease Modifying Drugs in Parkinson Disease: A Systematic Review & Meta-Analysis. [PDF]

Mov Disord Clin Pract
Rodrigues FR, Bolner G, Ribeiro GBES, Koppanatham A, da Silva RV, Fearon C, Schumacher Schuh AF, Bayram E, Couto JBM, Ushe M, Di Luca DG.   +10 more
europepmc   +1 more source

Differential effects of levodopa on social cognition in people with Parkinson's disease. [PDF]

J Parkinsons Dis
Danaila T, Métereau É, Klinger H, Jaulent A, Porte O, Tremblay L, Jaulent P, Laurencin C, Prange S, Thobois S.   +9 more
europepmc   +1 more source

Efficacy of GLP-1 receptor agonists in Parkinson's disease: a systematic review and exploratory network meta-analysis of randomized controlled trials. [PDF]

Neurol Sci
Ali M, Sharma A, Paruchuri A, Shahzad F, Khalid MB, B KN, Avanaki M, Nithyanandam A, Khan T, Suresh V.   +9 more
europepmc   +1 more source

The road for developing new pharmacological therapies for Parkinson's disease: Current trends and targets in clinical trials. [PDF]

J Parkinsons Dis
Machado T, Duarte GS, Outeiro TF, Ferreira JJ.   +3 more
europepmc   +1 more source

Medications Redistributed and Their Estimated Value from One Drug Repository Program. [PDF]

J Gen Intern Med
Gandhi A, Johnson DY, Hutchison AL, Matticks R, Laiteerapong N.   +4 more
europepmc   +1 more source